Nicotine and its derivatives are currently being synthesized and tested to explore their pharmaceutical potential for the treatment of Alzheimer's, Parkinson's, and other Central Nervous System (CNS) disorders. One area of research the Comins group has been undertaking is the development of methodologies for the synthesis of (S)-Nicotine derivatives using natural (S)-nicotine itself as an inexpensive starting material. An approach to (S)-Brevicolline, a natural product of the beta-carboline family that contains the core nicotine structure, will be discussed.
Back to Organic Chemistry - General Papers III
Back to The 57th Southeast/61st Southwest Regional Meeting (November 1-4, 2005)